Human Genome Epidemiology Literature Finder
Records 1 - 15 (of 15 Records) |
Query Trace: Thrombosis and meta-analysis and CYP2C19[original query] |
---|
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Molecular biology reports 2011 Mar 38 (3): 1697-702. Jin Bo, Ni Huan-Chun, Shen Wei, Li Jian, Shi Hai-Ming, Li Yo |
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. Journal of the American College of Cardiology 2010 Jul 56 (2): 134-43. Hulot Jean-Sébastien, Collet Jean-Philippe, Silvain Johanne, Pena Ana, Bellemain-Appaix Anne, Barthélémy Olivier, Cayla Guillaume, Beygui Farzin, Montalescot Gill |
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The pharmacogenomics journal 2011 Jun 11 (3): 199-206. Sofi F, Giusti B, Marcucci R, Gori A M, Abbate R, Gensini G |
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (Clinical research ed.) 2011 343 d4588. Bauer Tim, Bouman Heleen J, van Werkum Jochem W, Ford Neville F, ten Berg Jurriën M, Taubert Di |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart (British Cardiac Society) 2011 Jun . Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R |
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. Journal of thrombosis and haemostasis : JTH 2011 Nov . Li Y, Tang HL, Hu YF, Xie HG |
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian heart journal 2012 64 (4): 4. Singh M, Shah T, Adigopula S, Molnar J, Ahmed A, Khosla S, Arora R |
Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. The American journal of cardiology 2012 Aug 110 (4): 502-8. Jang Jae-Sik, Cho Kyoung-Im, Jin Han-Young, Seo Jeong-Sook, Yang Tae-Hyun, Kim Dae-Kyeong, Kim Dong-Soo, Seol Sang-Hoon, Kim Doo-Il, Kim Bo-Hyun, Park Yong Hyun, Je Hyung-Gon, Jeong Young-Hoon, Lee Seung-Wh |
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Archives of cardiovascular diseases 2013 Oct 106 (10): 517-27. Mao Liu, Jian Chen, Changzhi Liu, Dan Huang, Suihua Huang, Wenyi Tang, Wei |
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circulation. Cardiovascular genetics 2014 Dec 7 (6): 895-902. Sorich Michael J, Rowland Andrew, McKinnon Ross A, Wiese Michael |
Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017 22 109. Huang Bo, Cui De-Jun, Ren Ying, Han Bin, Yang Da-Ping, Zhao X |
The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Platelets 2020 6 31 (8): 971-980. Lyu Si-Qi, Yang Yan-Min, Zhu Jun, Wang Juan, Wu Shuang, Zhang Han, Shao Xing-Hui, Ren Jia-Me |
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y Inhibitor Therapy: A Meta-Analysis. JACC. Cardiovascular interventions 2021 Apr 14 (7): 739-750. Pereira Naveen L, Rihal Charanjit, Lennon Ryan, Marcus Gil, Shrivastava Sanskriti, Bell Malcolm R, So Derek, Geller Nancy, Goodman Shaun G, Hasan Ahmed, Lerman Amir, Rosenberg Yves, Bailey Kent, Murad M Hassan, Farkouh Michael |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials. Journal of clinical pharmacy and therapeutics 2022 4 47 (8): 1112-1121. Sheng Xiao-Yan, An Hui-Jie, He Yong-Yang, Ye Yong-Feng, Zhao Jia-Lan, Li S |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovascular revascularization medicine : including molecular interventions 2022 1 41 115-121. Malik Aaqib H, Gupta Rahul, Chakraborty Sandipan, Mahajan Pranav, Bandyopadhyay Dhrubajyoti, Yandrapalli Srikanth, Zaid Syed, Sreenivasan Jayakumar, Chaturvedi Abhishek, Mehta Sanjay S, Vyas Apurva V, Patel Nainesh C, Combs William G, Ahmad Has |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: